🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our new publication consists of a review of the current and potential use of voice-based technologies in cardiovascular care and clinical trials. Link: europepmc.org/article/med/34… Pishoy Gouda Elie Ganni Varinder Kaur Randhawa Guillaume Marquis-Gravel Robert Avram Justin Ezekowitz #Research

This publication looks at therapeutic hesitancy in initiating SGLT2-i and GLP-1 agonists for treatment of heart failure. Discover how a multi-faceted approach with technology can help motivate change: journals.lww.com/co-cardiology/… Haya Aziz Elizabeth Swiggum, MD Shelley Zieroth McGill University

Our review looking at current and potential use of voice-based technologies in cardiovascular care and clinical trials is now available on Medium. dreamcvlab.medium.com/voice-based-as… Pishoy Gouda Varinder Kaur Randhawa Guillaume Marquis-Gravel Robert Avram Justin Ezekowitz McGill University RI-MUHC Centre universitaire de santé McGill

RAASi therapy is often prescribed to patients with cardiovascular disease, who are more at risk of severe COVID-19. When hospitalized for COVID-19, is it best to continue or discontinue RAASi? Find out in this new paper by Dr. Abhinav Sharma. RI-MUHC bit.ly/3gGo5K2

We are working together to innovate diabetes care in Quebec. Our new partnership with health industry leaders aims to better diagnose #type2diabetes with AI-powered tech. DREAM-CV LAB Centre universitaire de santé McGill Fondation CUSM / MUHC Foundation MEDTEQ+ #HOPTech #DECIDECV Learn more: bit.ly/3jPU7F9

Learn more about the #DECIDECV program, a new innovative project using AI to improve #T2D care in Quebec: bit.ly/37DrTe7 DREAM-CV LAB Centre universitaire de santé McGill Fondation CUSM / MUHC Foundation MEDTEQ+ HOP Tech

Renseignez-vous au sujet du programme #DECIDECV, un nouveau projet novateur optimisant l’IA pour améliorer les soins du #DT2 au Québec : bit.ly/3v1Uwul DREAM-CV LAB Centre universitaire de santé McGill Fondation CUSM / MUHC Foundation MEDTEQ+ HOP Tech

Dr. Abhinav Sharma joins Elias Makos on CJAD 800 Montreal to discuss how artificial intelligence & machine learning are helping advance DECIDE-CV. An innovative partnership with Hop Tech, Boehringer Ingelheim, Centre universitaire de santé McGill, DREAM-CV LAB & MEDTEQ+. Learn more: bit.ly/39U81nY

🎧8 min to learn more about the DECIDE-CV program. A multi-disciplinary and collaborative project aimed at using #ArtificialIntelligence-based technologies to improve health outcomes for patients with type 2 #diabetes mellitus 👏Hop Tech Boehringer Ingelheim Fondation CUSM / MUHC Foundation DREAM-CV LAB

Plus tôt cette année, Abhinav Sharma, cardiologue et chercheur à l'IR-CUSM, a lancé le projet #DecideCV de détection précoce du diabète de type 2 à l’aide d’un bracelet connecté... lapresse.ca/actualites/sci… DREAM-CV LAB Centre universitaire de santé McGill Fondation CUSM / MUHC Foundation MEDTEQ+

Découvrez le projet fascinant, DREAM-CV LAB et l’association de HOP Tech avec le Dr Abhinav Sharma, un chercheur du Centre universitaire de santé McGill et RI-MUHC pour aider à prévenir le diabète de type 2 grâce à l’intelligence artificielle. Pour lire la suite La Presse : bit.ly/3haA5Ye

Very powerful message by Marc Bains at the #HFupdate2023 congress! Increased education about the new evidence-based therapies and recent innovations to better diagnose and treat heart failure is key to improve patient's outcomes and quality of life!#HeartLifeCanada CHFS

Dr. Abhinav Sharma, Principle Investigator of Dream-CV Lab presenting an interactive case study at the symposium " The Importance of sequencing GDMT" as part of of #HFUpdate congress 2023.

It’s day 2️⃣! We are #excited for another day of congress filled with science, discussions, clinical pearls, #HFA millionaire quiz 🏆 and lots of opportunities to meet old and new friends! ✨ Abhinav Sharma highlights why he is excited to be at #HeartFailure2023 #HFAMotions

Dr. Sharma presenting on time to statistical benefits in the CANVAS program and CREDENCE trial at the ESC-HFA Congress in Prague. Overall, statistical benefit shows up within 45 days for heart failure outcomes. #HeartFailure2023 European Society of Cardiology

Come, join our team!

Congratulations to Postdoctoral Fellow Orhun Kose for receiving the CHF alliance fellowship award. Thanks CHF alliance for the financial support. rimuhc.ca/en/-/ri-muhc-t…

Congratulations to RI-MUHC trainee Orhun Kose, who has won the CHF Alliance Trainee Award with work that will help patients with heart failure and other cardiometabolic diseases → tinyurl.com/3z5tuawh

Looking for a postdoctoral position and interested in evaluating the use of digital health technologies in patients with cardiovascular disease? Do you have a background in computer science or bioengineering? Details in the next post

We are hiring! Postdoctoral, PhD, and Masters positions available.